黑人女性妇科癌症临床试验的价值评估:我能从中得到什么
该研究系统评估了1994年至2021年间美国国立癌症研究所资助的279项妇科癌症临床试验方案,是否包含对黑人个体最重要的价值回报条目。结果显示,试验多包含基本信息、病历信息和影像学等价值条目,但生活方式风险因素、祖先信息、与其他参与者联系及报酬等条目极少或缺失。作者认为,在改善临床试验入组多样性的努力中,应考虑纳入黑人个体所重视的条目。
要点
- 279项妇科癌症临床试验中,仅1%包含生活方式风险因素信息,无试验包含祖先信息、参与者联系或报酬条目。
- 遗传检测(3%升至51%)和生物标志物检测(14%升至78%)价值条目比例随时间显著增加。
- 作者建议在改善临床试验入组多样性的多管齐下努力中,考虑纳入黑人个体所重视的价值条目。
核心结论
- 妇科癌症临床试验包含的能为黑人个体提供高价值的设计要素很少,如生活方式风险因素、祖先信息和报酬。
- 在改善临床试验入组多样性的任何多管齐下努力中,应考虑纳入黑人个体所重视的条目。
研究设计与样本
- 查询ClinicalTrials.gov数据库,纳入1994年1月至2021年11月间美国国立癌症研究所资助的美国妇科癌症临床试验,共279项。
- 从每项方案中提取预设的价值回报条目,计算各条目的纳入比例,并使用卡方检验评估时间变化趋势,进一步通过斜率和偏离线性计算评估比例趋势的时间性。
主要发现
- 多数试验首次入组时间在2001-2007年(37%),涉及卵巢癌(48%)、II期研究(53%)、化疗(60%)或靶向治疗(34%)。
- 试验常在基本信息(99%)、病历信息(99%)和影像学(82%)中纳入价值回报条目。
- 41%的试验在生物标志物检测中纳入价值回报条目,20%在遗传检测中纳入,20%在患者报告结局问卷中纳入。
- 随时间推移,纳入遗传检测(3%升至51%,p < 0.001)和生物标志物检测(14%升至78%,p < 0.001)的试验比例显著增加。
- 关于生活方式风险因素的信息很少(1%);没有试验在祖先信息、如何与其他参与者联系或报酬方面纳入价值回报条目。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Underrepresented groups may be dissuaded from clinical trial participation without perceived value. We therefore comprehensively assessed gynecologic cancer clinical trial protocols for the inclusion of items of value most important to Black individuals. METHODS: ClinicalTrials.gov was queried for NCI-sponsored gynecologic cancer clinical trials in the US between Jan.1994 and Nov.2021. Pre-specified return of value (ROV) items were abstracted from each protocol. Inclusion proportions were calculated for each ROV item and temporal changes assessed with chi-square tests. Temporality of proportional trends was further assessed by slope and departure from linearity calculations. RESULTS: 279 gynecologic cancer clinical trials were included. Most commonly trials had first accrual in 2001-2007 (37%) and involved ovarian cancer (48%), phase II studies (53%), and chemotherapy (60%) or targeted therapy (34%). Trials often included ROV items in basic information (99%), medical record information (99%), and imaging (82%). 41% of trials included ROV items in biomarker testing, 20% genetic testing, and 20% in patient-reported outcome questionnaires. Over time, there were significant increases in the proportion of trials that included genetic (3% to 51%; p < 0.001) and biomarker testing (14 to 78%, p < 0.001). Information on lifestyle risk factors was rare (1%). No trials included ROV items in ancestry, how to connect with other participants, or remuneration. CONCLUSIONS: Gynecologic cancer clinical trials include few design elements that provide high value to Black individuals like lifestyle risk factors, ancestry, and remuneration. In any multi-pronged effort to improve diversity in clinical trial enrollment, inclusion of items valued by Black individuals should be considered.
引用
- Oluloro A, Temkin SM, Jackson J, et al. What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women. Gynecol Oncol. 2023. PMID: 36931101. doi:10.1016/j.ygyno.2023.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。